Great Point Partners LLC 13F holdings, Q2 2026
Holdings as of June 30, 2026 · filings on SEC EDGAR · this is the latest filing on record
Great Point Partners LLC disclosed 37 US equity positions worth $424.4m in its Q2 2026 13F filing. The largest position was VOR at 7.4% of the reported book, followed by ABVX and VERA. Against the Q1 2026 filing, it opened 11 new positions, added to 7 and reduced 9 among the top 37 holdings.
What did Great Point Partners LLC own in Q2 2026? Top 37 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2026 |
|---|---|---|---|---|---|---|---|
| 1 | VOR VOR BIOPHARMA INC | Healthcare | 7.4% | $31.3m | 1,700,000 | -3% | reduced |
| 2 | ABVX ABIVAX SA | Healthcare | 6.4% | $27.2m | 204,314 | – | new |
| 3 | VERA VERA THERAPEUTICS INC | Healthcare | 6.1% | $25.8m | 600,836 | 201% | added |
| 4 | ZURA ZURA BIO LTD | Healthcare | 5.9% | $24.9m | 4,215,930 | 0% | held |
| 5 | ALMS ALUMIS INC | Healthcare | 5.7% | $24.1m | 856,061 | 0% | held |
| 6 | SOL-GEL TECHNOLOGIES LTD | 4.8% | $20.3m | 274,363 | 0% | held | |
| 7 | DFTX DEFINIUM THERAPEUTICS INC | Healthcare | 4.7% | $20.0m | 425,000 | – | new |
| 8 | ANNX ANNEXON INC | Healthcare | 4.7% | $20.0m | 3,500,000 | 40% | added |
| 9 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 4.1% | $17.4m | 183,330 | 0% | held |
| 10 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 3.9% | $16.7m | 855,813 | 71% | added |
| 11 | SGMT SAGIMET BIOSCIENCES INC | Healthcare | 3.7% | $15.7m | 2,029,933 | – | new |
| 12 | CTNM CONTINEUM THERAPEUTICS INC | 3.6% | $15.1m | 921,481 | 15% | added | |
| 13 | IMMX IMMIX BIOPHARMA INC | 3.1% | $13.2m | 1,277,642 | 265% | added | |
| 14 | CLYM CLIMB BIO INC | Healthcare | 3.1% | $13.0m | 1,000,000 | -25% | reduced |
| 15 | AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 3.0% | $12.6m | 700,000 | -60% | reduced |
| 16 | NKTR NEKTAR THERAPEUTICS | Healthcare | 2.9% | $12.2m | 175,000 | -45% | reduced |
| 17 | NGNE NEUROGENE INC | 2.6% | $11.1m | 352,180 | -30% | reduced | |
| 18 | LB PHARMACEUTICALS INC | 2.4% | $10.3m | 317,221 | 6% | added | |
| 19 | IRD OPUS GENETICS INC | 1.9% | $8.1m | 1,970,187 | 507% | added | |
| 20 | EPRX EUPRAXIA PHARMACEUTICALS INC | 1.9% | $7.9m | 1,200,000 | 0% | held | |
| 21 | DRUG BRIGHT MINDS BIOSCIENCES INC | Healthcare | 1.8% | $7.7m | 109,603 | -50% | reduced |
| 22 | INFLARX NV | 1.6% | $6.8m | 3,046,557 | – | new | |
| 23 | RLMD RELMADA THERAPEUTICS INC | Healthcare | 1.4% | $5.8m | 842,106 | 0% | held |
| 24 | JATT II ACQUISITION CORP | 1.3% | $5.7m | 500,000 | – | new | |
| 25 | CGEM CULLINAN THERAPEUTICS INC | Healthcare | 1.3% | $5.5m | 300,000 | 0% | held |
| 26 | ALT ALTIMMUNE INC | Healthcare | 1.2% | $5.3m | 1,741,232 | – | new |
| 27 | AMANAT ACQUISITION CORP | 1.2% | $5.1m | 500,000 | – | new | |
| 28 | RZLT REZOLUTE INC | 1.2% | $4.9m | 951,809 | 0% | held | |
| 29 | SLN SILENCE THERAPEUTICS PLC | 1.2% | $4.9m | 450,000 | -56% | reduced | |
| 30 | PALI PALISADE BIO INC | Healthcare | 1.1% | $4.8m | 2,284,819 | -33% | reduced |
| 31 | EVMN EVOMMUNE INC | 1.0% | $4.3m | 325,000 | 0% | held | |
| 32 | SCYX SCYNEXIS INC | 0.9% | $3.8m | 944,292 | – | new | |
| 33 | ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 0.8% | $3.6m | 70,000 | – | new |
| 34 | HUMA HUMACYTE INC | 0.7% | $2.9m | 3,750,000 | 0% | held | |
| 35 | RNTX REIN THERAPEUTICS INC | 0.6% | $2.7m | 2,575,000 | – | new | |
| 36 | DBVT DBV TECHNOLOGIES S A | 0.6% | $2.6m | 156,906 | – | new | |
| 37 | PROMIS NEUROSCIENCES INC | 0.3% | $1.1m | 86,150 | -77% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.